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Abstract 
Human induced pluripotent stem cells (hiPSC) have enabled a major step forward in pathophysiologic studies of 
inherited diseases and may also prove to be valuable in in vitro drug testing. Long QT syndrome (LQTS), characterized 
by prolonged cardiac repolarization and risk of sudden death, may be inherited or result from adverse drug effects. 
Using a microelectrode array platform, we investigated the effects of six different drugs on the electrophysiological 
characteristics of human embryonic stem cell‑derived cardiomyocytes as well as hiPSC‑derived cardiomyocytes from 
control subjects and from patients with type 1 (LQT1) and type 2 (LQT2) of LQTS. At baseline the repolarization time 
was significantly longer in LQTS cells compared to controls. Isoprenaline increased the beating rate of all cell lines 
by 10–73 % but did not show any arrhythmic effects in any cell type. Different QT‑interval prolonging drugs caused 
prolongation of cardiac repolarization by 3–13 % (cisapride), 10–20 % (erythromycin), 8–23 % (sotalol), 16–42 % (qui‑
nidine) and 12–27 % (E‑4031), but we did not find any systematic differences in sensitivity between the control, LQT1 
and LQT2 cell lines. Sotalol, quinidine and E‑4031 also caused arrhythmic beats and beating arrests in some cases. 
In summary, the drug effects on these patient‑specific cardiomyocytes appear to recapitulate clinical observations 
and provide further evidence that these cells can be applied for in vitro drug testing to probe their vulnerability to 
arrhythmia.
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Background
Inherited long QT syndrome (LQTS) is a potentially 
severe arrhythmic disease that affects the electrical repo-
larization of the myocardium and manifests as an abnor-
mally long QT interval on electrocardiogram (ECG) 
recordings. LQTS may result in polymorphic ventricular 
tachycardias known as torsades de pointes (TdP), which 
can ultimately lead to life-threatening ventricular fibrilla-
tion and sudden cardiac death (Schwartz et al. 2013).
Inherited forms of LQTS typically result from muta-
tions in cardiac ion channel coding genes. In the case 
of LQT type 1 (LQT1), the mutations are present in 
the KCNQ1 gene which encodes the α-subunit of the 
slow component of the delayed rectifier potassium cur-
rent (Kv7.1) (Wang et al. 1996), whereas LQT2 is caused 
by mutations of the KCNH2 gene which encodes the 
α-subunit of the rapid component of the delayed rectifier 
potassium current (Kv11.1) (Sanguinetti et al. 1995). Four 
founder mutations in these two genes have been found to 
explain the high (0.4 %) prevalence of LQTS in the Finn-
ish population (Marjamaa et  al. 2009). The most preva-
lent of these founder mutations is the C-terminal KCNQ1 
G589D missense mutation, resulting in a dysfunctional 
assembly domain and preventing the formation of fully 
functional potassium channel tetramers (Piippo et  al. 
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2001). Another prevalent but apparently milder founder 
mutation, the KCNH2 R176W missense mutation, 
resides in the N-terminus of the channel and accelerates 
the deactivation of the IKr tail current, thus leading to 
reduced potassium efflux (Fodstad et al. 2006). Research 
on the exact effects of these mutations on the functional 
properties of cardiomyocytes has been hampered by the 
lack of suitable techniques that can adequately recapitu-
late the full spectrum of the disease in vitro.
Human induced pluripotent stem cell (hiPSC) tech-
nology has recently made it possible to produce human 
cell lines with characteristics similar to those of embry-
onic stem cells from somatic cells of various origins 
(Takahashi et al. 2007; Yu et al. 2007). To date, multiple 
disease-specific hiPSC lines have already been estab-
lished (Wu and Hochedlinger 2011). Several studies have 
focused on LQTS using the hiPSC technology (Bellin 
et al. 2013; Itzhaki et al. 2011; Kiviaho et al. 2015; Lahti 
et al. 2012; Matsa et al. 2011, 2014; Moretti et al. 2010). 
These studies suggest that hiPSC technology may be use-
ful for modeling LQTS in  vitro. Until now, large-scale 
drug effects have been studied with human embryonic 
stem cell-derived cardiomyocytes (hESC-CMs) and wild-
type hiPSC-CMs (Braam et  al. 2010; Caspi et  al. 2009; 
Harris et al. 2013; Mehta et al. 2013; Navarrete et al. 2013; 
Yokoo et al. 2009). In this study, we investigated the effect 
of six clinically used drugs in control hESC- and wild-
type hiPSC-CMs and in hiPSC-derived LQT-CMs. Addi-
tional value will be gained by studying drug responses at 
clinically relevant concentrations (Schulz and Schmoldt 
2003), since many of the mutation carriers can have a 
latent, subclinical form of LQTS that may be exacerbated 
upon pharmacological challenge (Roden 2004).
We created hiPSC lines from the dermal fibroblasts of 
patients with KCNQ1 G589D and KCNH2 R176W muta-
tions. We investigated how these patient-specific hiPSCs 
respond to pharmacological challenges in comparison with 
cardiomyocytes derived from control hESCs and hiPSCs.
Methods
Patient‑specific pluripotent stem cell induction
The LQT1- and 2-specific hiPSCs were induced as previ-
ously described (Takahashi et  al. 2007) from fibroblasts 
of patients carrying the KCNQ1 (G589D) or the HERG 
(R176W) mutation (Fodstad et  al. 2004) (see Addi-
tional file 1: Materials and methods). The study has been 
approved by Pirkanmaa Hospital District ethical com-
mittee (R08070). Details of the hiPSC lines are listed in 
Table 1. The subjects volunteered for the study gave their 
consent for skin biopsy to be taken.
Stem cell culture
The control pluripotent stem cell lines used in this study 
were H7 (hESC, WiCell), UTA.00112.hFF [fetal wild-type 
from ATCC (WT)-hiPSC], and UTA.01006.WT (WT-
hiPSC derived from a healthy adult). For LQT1, 4 patient-
specific hiPSC lines were used: UTA.00208.LQT1, 
UTA.00211.LQT1, UTA.00313.LQT1 and UTA.00303.
LQT1. For LQT2 2 patient-specific hiPSC lines were 
used: UTA.00514.LQT2 and UTA.00525.LQT2. The 
pluripotent stem cells were cultured on a mouse embry-
onic fibroblast (MEF, Millipore) feeder cell layer in KSR 
medium consisting of KnockOut Dulbecco’s Modified 
Eagle’s Medium (KO-DMEM, Invitrogen) supplemented 
with 20 % KnockOut serum replacement (KO-SR, Invit-
rogen), 1  % non-essential amino acids (NEAA, Lonza), 
1  % Glutamax (Invitrogen), 50  U/mL penicillin/strepto-
mycin (Lonza), and recombinant human basic fibroblast 
growth factor (R&D Systems). The cells were passaged 
once a week by treating the pluripotent stem cell colo-
nies with collagenase IV (Gibco) and seeding them onto a 
fresh MEF feeder layer.
Table 1 Details of the control and patient-specific pluripotent stem cell lines used for drug testing
ICM inner cell mass of blastocyst, hFF human foreskin fibroblast, hADF human adult dermal fibroblast, hESC human embryonic stem cell, hiPSC human induced 
pluripotent stem cell
* Siblings ‡, θ, ψ  clonal lines from same individual s symptomatic a asymptomatic
Cell line Line type Mutation Disease Affected current Source Purpose
H7 (hESC) hESC Wild type None None ICM hESC control
UTA.00112.hFF (WTa) hiPSC Wild type None None hFF Control
UTA.01006.WT (WTb) hiPSC Wild type None None hADF Adult control
UTA.00208.LQT1θ,*,s hiPSC G589D LQT1 IKs hADF Symptomatic, patient‑specific
UTA.00211.LQT1θ,*,s hiPSC G589D LQT1 IKs hADF Symptomatic, patient‑specific
UTA.00303.LQT1ψ,*,a hiPSC G589D LQT1 IKs hADF Asymptomatic mutation carrier‑specific
UTA.00313.LQT1ψ,*,a hiPSC G589D LQT1 IKs hADF Asymptomatic mutation carrier‑specific
UTA.00514.LQT2‡,a hiPSC R176W LQT2 IKr hADF Asymptomatic mutation carrier‑specific
UTA.00525.LQT2‡,a hiPSC R176W LQT2 IKr hADF Asymptomatic mutation carrier‑specific
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Cardiomyocyte differentiation
Cardiomyocytes were differentiated from hESCs as well 
as from the control and LQT1 and -2-specific hiPSCs 
using the mouse visceral endoderm-like (END-2) cell co-
culture method, as described elsewhere (Mummery et al. 
2003). Briefly, mitomycin C (Sigma) -inactivated END-2 
cells were trypsinized and plated onto 12-well plates in 
0 % KO-SR hES medium. The pluripotent stem cells were 
plated on top of the END-2 cell monolayer the following 
day. The 0 % KO-SR hES medium was refreshed on days 
5, 8 and 12. At day 14, the medium was changed to 10 % 
KO-SR hES medium, and it was refreshed three times a 
week thereafter.
Pharmacological testing
Drugs
Cisapride monohydrate, quinidine and (±)-sotalol hydro-
chloride were obtained from Sigma-Aldrich and dis-
solved in dimethyl sulfoxide (Sigma-Aldrich) at 10 mM. 
E-4031 (Alomone Labs) and erythromycin (Abboticin 
i.v., Amdipharm) were dissolved in sterile H2O at 1 and 
50  mg/mL, respectively. Isoprenaline (Isuprel i.v., Hos-
pira) was supplied in ready-to-use ampoules. The drug 
concentrations were chosen based on their therapeutic 
blood serum concentration range (Schulz and Schmoldt 
2003). The following concentrations of cisapride mono-
hydrate, quinidine, (±)-sotalol hydrochloride, and eryth-
romycin were tested: half the concentration of the lower 
limit for the therapeutic blood serum concentration, the 
lower limit of the therapeutic blood serum concentra-
tion range, the average therapeutic serum concentra-
tion, the upper limit of the therapeutic range, and twice 
the upper limit of the therapeutic concentration (Schulz 
and Schmoldt 2003). The isoprenaline concentrations 
were chosen according to previously published values 
and multiples thereof (Pekkanen-Mattila et  al. 2009). 
The drugs were serially diluted in embryoid body (EB)-
medium with 5  % fetal bovine serum (FBS, see below). 
The test concentrations for each drug are listed in Table 2.
Multielectrode array recordings
The hESC-CMs and the control, LQT1-, and LQT2-
specific hiPSC-CM aggregates were mechanically 
excised from the cultures and plated onto fetal bovine 
serum (PAA) and 0.1  % gelatin- (Sigma-Aldrich) coated 
6-well-MEAs (6wellMEA200/30iR-TI-mr, MultiChan-
nel Systems MCS GmbH). The FPs were recorded with a 
USB-MEA1060 amplifier, and the temperature was kept 
at +37 °C using a TC02 heating element (both from Multi 
Channel Systems MCS GmbH). The MEAs were cov-
ered with gas-permeable MEA membranes (ALA MEA-
SHEET, ALA Scientific) during the recordings. A wash-in 
time of 2  min was allowed for the drugs before record-
ings. The beating areas were cultured in EB medium 
consisting of KO-DMEM (Invitrogen) supplemented 
with 20 % FBS (Invitrogen), 1 % NEAA (Lonza), 1 % Glu-
tamax (Invitrogen), and 50 U/mL penicillin/streptomycin 
(Lonza). The drug tests were performed in 5 % FBS con-
taining EB medium; the medium was changed at least an 
hour prior to the baseline recordings, and the cells were 
allowed to stabilize in the incubator (+37 °C, 5 % CO2). 
The field potential signals were recorded with MC_Rack 
v.4.0.0 software (Multi Channel Systems MCS GmbH).
Data and statistical analysis
The field potential durations (FPDs) from the recorded 
files were measured offline using our in-house devel-
oped CardioMDA software (Pradhapan et  al. 2013) and 
AxoScope10 (Molecular Devices). The baseline data 
are presented as mean  ±  standard deviation (SD). Lin-
ear mixed-effect models with either Bazett’s corrected 
field potential duration (cFPD) or beating rate (BR) as a 
dependent variable were fitted using the function lme in 
R (Software environment for statistical computing and 
graphics, version 2.13.0, The R Foundation for Statistical 
Computing). The factorial variable for the concentration 
level was used as an independent variable. The lowest 
concentration level was used as a reference group. Ran-
dom intercept for different aggregates was used together 
with independent random errors.
Results
LQT patient characteristics
Skin biopsies were obtained from two siblings, a 28-year 
old female asymptomatic LQT1 patient (QTc interval, 
428  ms) and a 41-year old female symptomatic LQT1 
patient (QTc interval, 456  ms), both with the KCNQ1 
G589D mutation. In addition, skin biopsies were 
obtained from a 61-year old male asymptomatic LQT2 
patient with the KCNH2 R176W mutation (QTc inter-
val, 437  ms). The symptomatic LQT1 patient had expe-
rienced seizures before beta-blocker medication, while 
the asymptomatic sibling has never had any cardiac 
Table 2 Drugs and  their concentrations used with  cardio-
myocytes derived from  human embryonic and  induced 
pluripotent stem cells
Drug Concentrations
Isoprenaline nM: 81, 402
Cisapride monohydrate nM: 40, 83, 120, 165, 330
Erythromycin µM: 1.5, 3, 5.5, 8, 16
Sotalol µM: 0.8, 1.6, 5.7, 9.7, 19.4
Quinidine µM: 1.5, 3, 9, 15, 30
E‑4031 nM: 10, 100, 300, 500, 700
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symptoms. The asymptomatic LQT2 individual has only 
experienced occasional palpitations, which although are 
not specific symptoms of LQTS.
Molecular characteristics of cardiomyocytes
Reverse-transcription PCR and immunofluorescence 
microscopy showed that the control and LQT-hiPSCs 
expressed the pluripotency markers NANOG, OCT3/4, 
SOX2, SSEA4, TRA-1-60, and TRA-1-81 (Additional 
file 1: Fig. S1A, Table S1). Furthermore, the hiPSC colony 
morphology resembled those of hESCs, the hiPSCs dif-
ferentiated into cardiomyocytes at efficiencies previously 
reported for hESCs upon END-2 co-culture (data not 
shown) (Pekkanen-Mattila et  al. 2009), showed nuclear 
localization of the cardiac-specific transcription factor 
NKX2.5 which is also expressed in hESC-CMs (Asp et al. 
2010), and exhibited a distinct striated pattern in car-
diac troponin T staining (Additional file 1: Fig. S1B). The 
electrophysiological properties and drug responses were 
recorded with microelectrode arrays (MEAs).
Effects of cardioactive drugs to the cFPD of hiPSC‑CMs
We compared the drug responses of the control cardio-
myocytes derived from hESC line H7 (hereafter called 
hESC) and two wild-type hiPSC lines UTA.00112.hFF 
(hereafter called WTa) and UTA.01006.WT (hereafter 
called WTb) to the hiPSC-derived LQT-CMs (for the 
cell line properties, see Table 1). The results of the clonal 
cell lines derived from the same individual were pooled 
together (UTA.00208.LQT1 and UTA.00211.LQT1 
[=LQT1A], UTA.00303.LQT1 and UTA.00313.LQT1 
[=LQT1B], UTA.00514.LQT2 and UTA.00525.LQT2 
[=LQT2]). LQT1A were derived from a symptomatic 
patient, LQT1B from an asymptomatic mutation carrier 
and LQT2 from asymptomatic mutation carrier.
Baseline characteristics
The baseline beating rates (BR) showed large differences 
between cell populations, ranging from 59 to 105 beats 
per minute (Fig.  1a). However, these BRs did not dif-
fer significantly among cardiomyocytes differentiated 
from hESCs, control-, or LQT-hiPSCs. In contrast, the 
beating rate-corrected field potential duration (cFPD, 
Bazett´s) showed significant differences between control- 
and LQT-CMs (Fig. 1b). At baseline level, the LQT-CMs 
showed significantly longer cFPD (586–600  ms) com-
pared to control-CMs (340–400 ms) (p < 0.001).
Isoprenaline effects
To test whether the differentiated cardiomyocytes had 
proper β-adrenergic responses, we subjected them to an 
isoprenaline challenge. This treatment had chronotropic 
effect on cardiomyocytes and increased the BR at the 
concentration of 81 and 402 nM (Fig. 2). Isoprenaline did 
not induce any arrhythmic beats in any of the CMs, includ-
ing those derived from LQT1- and LQT2-hiPSC lines.
Effects of non‑cardiac drugs cisapride and erythromycin
Cisapride increased the repolarization time in all CMs 
studied, although this effect did not reach statistical sig-
nificance in the LQT2-CMs, apparently due to large 
experimental variation (Fig. 3a).
Erythromycin likewise induced a significant average 
increase of cFPD in all cell lines studied, in a concentra-
tion range of 1.5–16 µM (Fig. 3b). No arrhythmic beats 
or beating arrests were observed with cisapride or with 
erythromycin.
Effects of the anti‑arrhythmic drugs sotalol and quinidine
Upon sotalol (0.8–19.4 µM) challenge, the maximal cFPD 
prolongation ranged from of 8  % (WTb-CMs) to 23  % 
(LQT1A-CMs) (Fig. 4a). Quinidine also caused a concen-
tration-dependent (1.5–30 µM) average cFPD prolonga-
tion in all the cardiomyocytes (Fig.  4b). Of all clinically 
used drugs tested (cisapride, erythromycin, sotalol, qui-
nidine), quinidine showed the largest cFPD-increasing 
effect (31–42 %) seen in LQT1-CMs.
The effect of the hERG channel blocker E‑4031
E-4031 also caused concentration-dependent cFPD pro-
longation in all cardiomyocyte types (Fig. 4c). It is of note 
that in hESC-CMs all but one of the cardiac aggregates 
became arrhythmic or stopped beating at concentrations 
of 500–700  nM. Thus, error bars indicating standard 
deviation could not be calculated for these experimental 
points. The cFPD prolongation in the different cell lines 
reached statistical significance at E-4031 concentration 
of 100 nM indicating that the sensitivities of the different 
cell lines to E-4031 were very similar (Fig. 4c).
In summary, Fig. 5 illustrates the representative traces 
of cisapride, erythromycin, sotalol, quinidine and E-4031 
in control- and LQT-CMs.
The proarrhythmic effects of sotalol, quinidine and E‑4031
Sotalol, quinidine and the hERG blocker E-4031 showed 
proarrhythmic effects on certain individual cell lines 
(Table 3). With sotalol, only spontaneous afterdepolariza-
tion (AD)-like waveform abnormalities (but not beating 
arrests) were observed (Table 3). Sotalol caused AD-like 
waveforms ranging from concentrations 5.7  µM (aver-
age therapeutic serum concentration) to 19.4 µM (twice 
the upper therapeutical serum concentration). None of 
the LQT1B-CMs showed any arrhythmic behavior upon 
sotalol challenge.
Quinidine showed also beating arrests in addition to 
AD-like waveform abnormalities (Table  3). The AD-like 
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waveforms were observed at the therapeutical serum 
concentration range (3–15  µM) in hESC-, LQT1A- and 
LQT2-CMs but not in WT- or LQT1B-CMs (Table  3). 
On the other hand, the beating arrests occurred ranging 
from 9 µM (average therapeutic serum concentration) to 
30 µM (twice the upper therapeutical serum concentra-
tion) (Table 3).
The compound E-4031 also caused AD-like wave-
form abnormalities and beating arrests (Table  3). 
E-4031 caused AD-like waveform abnormalities in car-
diomyocytes differentiated from all of the lines except 
WTb-CMs. Furthermore, beating arrests were seen in 
all cardiomyocyte types except LQT1A-CMs. Among 
the LQTs, the highest frequency for AD-like waveform 
abnormalities was found in LQT1A-CMs (50 % of cardio-
myocyte aggregates). On the other hand, the highest fre-
quency for beating arrests were seen in LQT2-CMs (31 % 
of cardiomyocyte aggregates).
Discussion
The present study further demonstrates the usefulness of 
the hiPSC-derived cardiomyocytes to serve as a model 
Fig. 1 Baseline cardiac parameters. a The beating rate (BR) of the cardiomyocyte clusters differentiated from each human induced pluripotent 
stem cell (hiPSC) line. b The rate‑corrected field potential duration (cFPD) for the same cardiomyocyte clusters. Significance level is indicated by 
***p < 0.001
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for long QT syndrome, showing that the QT interval-
prolonging effects of clinically used drugs are replicated 
in this in  vitro system, using concentrations that are 
within or close to their therapeutic range (Schulz and 
Schmoldt 2003). We showed that LQT-CMs corrected 
field potential duration is significantly longer than in con-
trol-CMs at baseline conditions, which suggests that long 
QT syndrome is recapitulated in these cells. This study 
also reproduces in cell clusters the earlier observation 
with single cells by patch clamp with prolonged APDs 
in LQT-CMs compared to controls (Kiviaho et al. 2015; 
Lahti et al. 2012). In the current study LQT- and control 
CMs were further exposed to various cardioactive drugs 
to investigate their effects.
The cardiomyocytes beating rates were increased by 
isoprenaline, which is a β-adrenergic agonist that affects 
calcium (ICa,L) channel activation via β1 receptors. This 
is in line with the previous studies showing positive 
chronotropic effect of isoprenaline on both hESC- and 
hiPSC-CMs (Moretti et al. 2010; Pekkanen-Mattila et al. 
2009; Yokoo et  al. 2009). β-adrenergic stimulation with 
isoprenaline did not have any arrhythmic effects on the 
LQT1 lines although LQT1 patients often experience 
symptoms at increased heart rates.
Cisapride is a serotonin 5-HT4 receptor agonist that 
has been reported to block the hERG potassium chan-
nel (Mohammad et al. 1997). It is known to induce TdP 
in patients (Darpö 2001). Caspi et  al. (2009) reported 
significant (>50  nM) dose-dependent prolongation of 
cFPD in hESC-CMs (Braam et al. 2010; Caspi et al. 2009). 
We obtained similar results as Caspi et al. (2009) as the 
hESC-CMs used in our study showed dose-dependent 
and significant cFPD prolongation starting at 83  nM. 
In contrast, Braam et  al. (2010) reported no significant 
cisapride-induced cFPD prolongation in hESC-CMs. 
However, they judged the therapeutic concentration to be 
2.6–4.9 nM (Redfern et al. 2003), whereas we chose the 
therapeutic range as 83–165  nM (Schulz and Schmoldt 
2003), which may explain the fact that they were not able 
to detect significant cisapride-induced cFPD prolonga-
tion. Mehta et al. (2013) have also investigated the effect 
of cisapride to the cFPD of 150–170  days old EB-based 
hiPSC-derived CMs. Likewise, they also found con-
centration-dependent cFPD prolongation (Mehta et  al. 
2013). Mehta et  al. (2013) did not observe any arrhyth-
mias with cisapride, which is in line with our study here.
Erythromycin is a macrolide antibiotic that pro-
longs the QT interval in patients (Shaffer et  al. 2002). 
The therapeutic plasma concentration of erythromycin 
has been reported to be 3–8  µM (Schulz and Schmoldt 
2003). In our study, erythromycin prolonged significantly 
cFPD in hESC-CMs already at the first test concentra-
tion (1.5  µM). Our data may suggest a slightly higher 
sensitivity of LQT2-CMs compared to LQT1-CMs, but 
high experimental variation precludes firm conclusions. 
Erythromycin did not induce any arrhythmic effects in 
the cardiomyocytes.
Sotalol is a β-adrenergic receptor antagonist and 
a Vaughan–Williams class III anti-arrhythmic agent 
that potently blocks the potassium ion channels in 
Fig. 2 Isoprenaline response of the control and long QT syndrome (LQT) type 1 and 2‑specific cardiomyocyte clusters (hESC, WTa, WTb, LQT1A, 
LQT1B and LQT2). Data is presented mean ± SD. Mean beating rates (BR) were normalized to baseline BR. Asterisks mark the statistical significance 
for mean BR increase compared to baseline values. *p < 0.05, **p < 0.01, ***p < 0.001
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cardiomyocytes (Edvardsson et al. 1980). In hESC-CMs, 
Braam et  al. (2010) reported cFPD prolongations of 
15–20 % at sotalol concentrations of 1.8–14 µM (Braam 
et  al. 2010). In a subsequent study, they also observed 
20  % cFPD prolongation in hESC-CMs at sotalol con-
centration of 10  µM (Braam et  al. 2013). Our study 
resulted in similar data. At concentrations of 6–10  µM, 
we observed a cFPD prolongation of 12–18  % in the 
hESC-CMs, increasing to 21  % at 19  µM. We observed 
that sotalol increased cFPD in all the CMs at the thera-
peutical concentration range (1.6–9.7  µM). In line with 
our data, Mehta et  al. (2013) reported similar observa-
tions from sotalol-induced cFPD prolongation in hiPSC-
derived CMs (Mehta et al. 2013). Furthermore, according 
to our data sotalol significantly increased cFPD at earlier 
concentrations in LQT-CMs than in WTa or WTb. This 
may suggest that LQT-CMs may be more vulnerable to 
the cFPD-prolonging effect of sotalol than hiPSC-derived 
control cells.
Quinidine is a class Ia antiarrhythmic drug that primar-
ily blocks sodium ion channels at high concentrations 
and hERG channel at low concentrations and is associ-
ated with TdP (Bauman et  al. 1984). Quinidine pro-
longed the cFPDs in all of our cell lines ranging from 16 
to 42  %. Braam et  al. (2010) reported a prolongation of 
20–50 % in hESC-CMs with quinidine concentrations of 
up to 3.2  µM and increases in the cFPD at higher con-
centrations, and Caspi et  al. (2009) reported a cFPD 
Fig. 3 Non‑cardiac drug responses of the control and long QT syndrome (LQT) type 1 and 2‑specific cardiomyocyte clusters (hESC, WTa, WTb, 
LQT1A, LQT1B and LQT2). The drugs used were a cisapride and b erythromycin. Changes in the rate‑corrected field potential duration (cFPD) 
were calculated as relative changes from the baseline for each cardiomyocyte cluster. Data is presented mean ± SD. Mean ΔcFPDs were normal‑
ized to baseline cFPD. Asterisks mark the statistical significance for mean ΔcFPD prolongation compared to baseline values. *p < 0.05, **p < 0.01, 
***p < 0.001
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Fig. 4 Class I and class III anti‑arrhythmic drug responses of the control and long QT syndrome (LQT) type 1 and 2‑specific cardiomyocyte clusters 
(hESC, WTa, WTb, LQT1A, LQT1B and LQT2). The drugs used were a sotalol, b quinidine and c E‑4031. During E‑4031 challenge all but one of the 
cardiac aggregates in hESC‑CMs became arrhythmic or stopped beating at concentrations of 500–700 nM. Thus, error bars indicating standard 
deviation could not be calculated for these experimental points. Changes in the rate‑corrected field potential duration (cFPD) were calculated as 
relative changes from the baseline for each cardiomyocyte cluster. Data is presented mean ± SD. Mean ΔcFPDs were normalized to baseline cFPD. 
Asterisks mark the statistical significance for mean ΔcFPD prolongation compared to baseline values. *p < 0.05, **p < 0.01, ***p < 0.001
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prolongation of slightly <30 % in hESC-CMs with 8 µM 
quinidine (Braam et  al. 2010; Caspi et  al. 2009). Mehta 
et al. (2013) reported a 20 and 55 % cFPD prolongation in 
150–170 days old hiPSC-CMs at 1 and 10 µM concentra-
tions, respectively. Here, we noticed an 18 % increase in 
the cFPD of the hESC-CMs at a concentration of 9 µM. 
Quinidine induced beating arrests which emerged at the 
average or upper therapeutic serum concentration. Qui-
nidine is known to inhibit sodium ion channels at high 
concentrations (Snyders and Hondeghem 1990), which 
may be the reason for higher frequency of beating arrest 
than AD-like waveform abnormalities. The LQT2-CMs, 
showed significantly prolonged cFPD already at the half 
of the lower limit of therapeutic concentration (1.5 µM), 
Fig. 5 Representative traces of cisapride, erythromycin, sotalol, quinidine and E‑4031 in control‑ and long QT‑cardiomyocytes (LQT‑CMs)
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unlike control- or LQT1-CMs, and AD-like waveform 
abnormalities at the lower limit of therapeutic concen-
tration level (3  µM). These findings together may imply 
that LQT2 harboring hERG R176  W may be at more 
increased risk for quinidine-induced cFPD prolongation 
and proarrhythmic effects than control- or LQT1-CMs 
harboring G589D mutation. However, we emphasize that 
our findings, based on cell lines derived from three LQTS 
patients only, must be interpreted with caution.
E-4031 is a hERG channel blocker (Caspi et  al. 2009) 
that reduced the IKr current during cardiac repolariza-
tion and caused prolongations in all our cell lines. Braam 
et  al. (2010) reported FPD prolongation in hESC-CMs 
treated with 30 nM E-4031 and AD-like waveform abnor-
malities at concentrations of 1 µM and over (Braam et al. 
2010). In hiPSC-CM clusters similar cFPD prolongations 
have been reported as well (Mehta et  al. 2011, 2014). 
We observed that the cFPD increased significantly more 
in CMs derived from symptomatic LQT1 patient than 
from asymptomatic. Presently, it is not known whether 
this indicates that symptomatic LQT1 may be at more 
increased risk for hERG blocker-induced cFPD increase. 
Egashira et al. (2012) reported cFPD prolongation of 20 % 
in LQT1-CMs derived from a symptomatic patient, when 
treated with 100  nM E-4031. These LQT1-CMs had a 
heterozygous deletion mutation in KCNQ1, 1893delC 
(Egashira et  al. 2012). Here, we found cFPD prolonga-
tion of 13 and 8 % in LQT1A- and LQT1B-CMs carrying 
a G589D missense mutation. Egashira et  al. (2012) also 
reported AD-like waveform abnormalities in LQT1-CMs 
treated with 300  nM E-4031, which is in line with our 
results from symptomatic LQT1A-CMs.
Variations of the in vitro responses to QTc interval affect-
ing drugs may result from several reasons. Differences 
in the common polymorphisms regulating cardiac repo-
larization may result in the modulation of drug responses 
(Roden 2004). Furthermore, differences in drug responses 
between the LQT1 and -2 subtypes may result from dif-
ferences in their respective repolarization reserves (Roden 
1998). Other possible explanations may come from the 
observations that hPSC-CMs can have very low or very 
high spontaneous beating rates, and that the hPSC-CMs 
with BR ≥  50  bpm express more atrial-related genes and 
therefore might be more atrial-like (Asp et  al. 2010). Dif-
ferent cardiomyocyte subtypes (e.g., atrial vs. ventricular) 
may have different ion channel compositions (Gaborit 
et al. 2007). Therefore, for certain applications, if the beat-
ing rates are representative of differences between cardiac 
subtypes, then the drug responses might vary accordingly. 
We did not test whether the END-2 differentiation protocol 
used in this study generated more nodal-, atrial- or ventric-
ular-like CMs across the cell lines. The MEA analysis used 
Table 3 Arrhythmic effects of sotalol, quinidine, and E-4031 observed during the field potential (FP) recordings
The reported values in the table are the lowest concentrations that induced the effect. The numbers in parentheses indicate how many cardiomyocyte clusters in total 
were affected
AD afterdepolarization (AD)-waveforms, BA beating arrest (termination of FP activity)
* Siblings s  symptomatic a asymptomatic
Sotalol (µM) hESC (n = 11) WTa (n = 6) WTb (n = 12) LQT1A (n = 13)*,s LQT1B (n = 13)*,a LQT2 (n = 15)a
0.8
1.6
5.7 AD(2)
9.7 AD(4) AD(1)
19.4 AD(1) AD(2)
Quinidine (µM) hESC (n = 10) WTa (n = 6) WTb (n = 11) LQT1A (n = 12)*,s LQT1B (n = 16)*,a LQT2 (n = 12)a
1.5
3 AD(1)
9 AD(3) BA(7) AD(1) BA(5) BA(5)
15 BA(2) BA(2)
30 BA(1)
E‑4031 (nM) hESC (n = 10) WTa (n = 6) WTb (n = 8) LQT1A (n = 16)*,s LQT1B (n = 16)*,a LQT2 (n = 13)a
10
100 BA(4)
300 AD(7) AD(2) AD(8) AD(3)
500 BA(1) BA(2) BA(1) AD(4)
700 BA(1)
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in the present study includes only beating clusters, suggest-
ing the presence of nodal-, atrial- and ventricular-like type 
of CMs. However, previous study has shown that END-2 
differentiation protocol generates mostly ventricular CMs 
shown by electrophysiological measurements (Mummery 
et al. 2003). It is also unknown whether the heterozygous 
mutated ion channels are assembled similarly in all differen-
tiating cardiomyocytes. Variation in the ion channel com-
position from cluster to cluster and even from cell to cell 
might lead to differential drug responses. There are some 
evidence that there may be differences in same certain drug 
responses between clusters of CMs and monolayer CMs. 
In disease-free hiPSC-CM monolayers, Harris et al. (2013) 
reported statistically significant E-4031 induced cFPD pro-
longation already at 3 nM whereas for disease-free clusters 
of hESC- or hiPSC-CMs the significant cFPD prolonga-
tions were reported to be found in 30–300 nM (Braam et al. 
2010; Caspi et al. 2009; Mehta et al. 2011, 2014). In disease-
free hiPSC-CM monolayers E-4031 evoked arrhythmias 
were seen as early as 10–30 nM (Harris et al. 2013; Naka-
mura et al. 2014). We have also observed similar phenom-
enon in monolayer-based disease-free CMs with E-4031 
(data not published). The aforementioned differences may 
have significant implications in drug screenings and would 
require further investigation.
Potential limitation of the study
The clinical phenotypes of the patients did not corre-
late with repolarization times in this study. The occur-
rence of clinical symptoms in LQT-patients harboring 
G589D have been linked to QTc value. In the group of 
QTc > 500 ms over 50 % of the patients were symptomatic 
whereas only 16 % were symptomatic with QTc < 440 ms 
(Piippo et al. 2001). In addition, patients with C-terminal 
mutation such as G589D have milder phenotypes com-
pared to transmembrane domain mutations of the same 
channel (Donger et  al. 1997; Larsen et  al. 1999; Piippo 
et  al. 2001; Swan et  al. 1999). In this study, the LQT1-
G589D-patients’ QTc values were 456 and 428  ms for 
symptomatic and asymptomatic, respectively. In LQT2, 
R176W mutation has been reported elsewhere as a rela-
tively mild form with modest QTc prolongation (Fodstad 
et al. 2006; Marjamaa et al. 2009). Here, the LQT2 patient 
had been asymptomatic except for occasional palpita-
tions. In the present study, at the baseline significant dif-
ferences in repolarization times were observed, but the 
drug effects appeared to be of similar magnitude in LQT-
CMs harboring G589D or R176W mutations compared 
to healthy controls at this sample size. Given the large 
variance in cFPD it may be possible that by increasing 
the sample size statistical significances could be found 
between control and LQT-CMs. However, it should be 
emphasized that increases in repolarization times which 
are already at baseline longer are potentially more severe 
that in those of normal length.
Conclusion
In conclusion, the present study reports in  vitro elec-
trophysiological effects of various non-cardiac and 
cardioactive drugs as assessed in hiPSC-derived LQT-
cardiomyocytes. We have shown that long QT syndrome 
is recapitulated in hiPSC-derived LQT-cardiomyocytes. 
All drugs tested showed a systematic tendency to prolong 
the field-potential duration (cFPD, an indicator of repo-
larization phase). We did not observe any systematic dif-
ferences in the sensitivities of cFPD prolongation among 
different drugs between control- and LQT-cardiomyo-
cytes. Further studies are needed to explore the possibil-
ity that this system could aid in the patient-specific risk 
assessment when considering the use of potentially QT-
interval prolonging drugs.
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